Singletto
Singletto is a biotechnology company revolutionizing antimicrobial protection for healthcare, military, industry, and consumer applications. Their core technology, Oxafence®, leverages Antimicrobial Photodynamic Inactivation (aPDI) using light-activated dyes to generate singlet oxygen, which inactivates viruses and bacteria on treated surfaces. Founded during the COVID-19 pandemic by Drs. James Chen and Thomas Lendvay, Singletto's mission is to deliver ongoing, science-driven Active Protection™ against current and emerging biological threats. The company collaborates with global health leaders, including the WHO and CDC, and partners with manufacturers to develop and commercialize innovative products that actively destroy pathogens during use. Singletto's work is validated by a robust body of peer-reviewed research and ongoing global collaborations.
Patents
What We Do
FDA-cleared ASTM Level 3 surgical masks incorporating Oxafence Active Protection technology, which inactivates 99.9% of tested viruses (including H1N1 Influenza and OC43 Coronavirus) after five minutes of contact. Developed in partnership with Prestige Ameritech, these masks are available in the U.S. and New Zealand.
Oxafence technology was incorporated into Teledyne FLIR’s Integrated Soldier Protective System (ISPS), a smart fabric suit under development for the U.S. Defense Advanced Research Projects Agency (DARPA) Personalized Protective Biosystems Program, to mitigate biological threats for frontline personnel.
Application Area
FDA Regulated Medical Devices
Key People
Chief Executive Officer
Chief Scientific Officer
Chief Medical Officer
Chief Operating Officer
Board Member, Chief Financial Officer, Strategic Advisor
Clinical Solutions
News & Updates
Singletto's Oxafence technology received FDA clearance for use in ProGear ASTM L3 Surgical Masks, now available in the U.S. and New Zealand.
The WHO-led DeMaND study, co-authored by Singletto's leadership, was published in Infection Control & Hospital Epidemiology, validating the efficacy of methylene blue and light for PPE decontamination.
Dr. Thomas Lendvay, Singletto’s Co-Founder and Chief Medical Officer, was recognized as a Top Doctor by Seattle Magazine.
GeekWire highlighted Singletto as a lead story, focusing on the FDA approval of its Oxafence Active Protection technology for surgical masks and the company's plans for expansion.
Peer-reviewed research, including studies by Singletto co-founders, confirmed the efficacy of Antimicrobial Photodynamic Inactivation (aPDI) against a range of dangerous viruses, supporting the core technology behind Oxafence.
An article by CEO John Bjornson introduces aPDI technology, recaps the WHO DeMaND study, and advocates for better PPE protection.
Article featuring Dr. Belinda Heyne on the perpetual decontamination ability of Light-Activated Dyes, highlighting the DeMaND study's findings.
CBC article featuring Dr. Belinda Heyne, discussing the use of methylene blue and light to decontaminate medical masks.
Publication of the peer-reviewed DeMaND study, validating the use of methylene blue and light for decontaminating masks and PPE.
Dr. Thomas Lendvay, Singletto’s Co-Founder and Chief Medical Officer, was named a 'Top Doctor' by Seattle Magazine for his work in pediatric urology and innovation in healthcare.
A study demonstrated that methylene blue photochemical treatment can effectively decontaminate norovirus-contaminated masks, supporting the use of Oxafence technology.
The World Health Organization updated its COVID-19 PPE guidelines to include Methylene Blue and Light as a supported decontamination method, citing the DeMaND Study led by Singletto co-founders. This method provides both decontamination and continuous inactivation of coronavirus on PPE.
Singletto's Oxafence technology was further developed and incorporated into Teledyne FLIR’s Integrated Soldier Protective System as part of the DARPA PPB Program, aimed at developing adaptive uniforms for protection against chemical and biological threats.
Oxafence was featured in a poster series at the Grand Challenges Annual Meeting in Dakar, Senegal, highlighting the DeMaND study and follow-on research on mask and N95 decontamination using Methylene Blue.
In partnership with Prestige Ameritech, Singletto launched ProGear+Oxafence ASTM L3 Masks in New Zealand, providing Active Protection from viruses for dental and individual customers.
Singletto launched Oxafence Mask Spray direct to consumers in New Zealand, offering ongoing protection from SARS-CoV-2 and the Flu virus on masks.
Singletto, in collaboration with the Kenya Medical Research Institute (KEMRI) and the Respiratory Society of Kenya (ReSoK), is developing a research proposal to evaluate the efficacy of Oxafence antimicrobial technology against Mycobacterium tuberculosis (TB) and to assess the acceptability of antimicrobial face masks in Kenyan healthcare settings.